FOS and ductal breast carcinoma in situ: 6c). In ERK1 knockout DCIS-iFGFR1 cells, activation of FGFR1 signaling by AP20187 treatment still upregulated both c-FOS and FOXQ1 proteins, and these upregulations were inhibited by T-5224.